Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter

Giuseppe Curigliano, Alessandra Balduzzi, Anna Cardillo, Raffaella Ghisini, Giulia Peruzzotti, Laura Orlando, Rosalba Torrisi, Silvia Dellapasqua, Loredana Lunghi, Aron Goldhirsch, Marco Colleoni

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: We previously demonstrated a high incidence (7.7%) of venous thromboembolism (VTE) in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheters (CVC). The aim of this study was to evaluate the efficacy and safety of low-dose aspirin for the prevention of VTE. Patients and methods: In a monocentric prospective study, patients with stage II-IV breast cancer, who underwent CVC insertion for continuous infusional chemotherapy, were assigned to receive low-dose aspirin (100 mg daily). Treatment was started after CVC implantation and continued until the last day of chemotherapy. Patients were assessed for safety and for the incidence of symptomatic deep venous thrombosis (DVT) confirmed by color-Doppler ultrasonography. Results: Between April 2000 and March 2004, 188 consecutive patients were included in the study. Median age was 48 years (range 22-83), 31 patients (16%) had concomitant hypertension, and 14 patients (7.4%) were smokers. Median duration of treatment with aspirin was 3.6 months (range 0.4-5.7). A DVT confirmed by color-Doppler ultrasonography was observed in four patients (2.1%; 95% confidence interval, 0.58-5.35%). Side effects included mild epistaxis (three patients, 1.5%) and mild gastric pain (two patients, 1%). No major bleeding complication or International Normal Ratio alteration occurred. Conclusions: Administration of low-dose aspirin is safe and seems to correlate with a low risk of DVT in breast cancer patients treated with infusional chemotherapy. Further randomized studies comparing low-dose aspirin with other anticoagulative agents are warranted.

Original languageEnglish
Pages (from-to)1213-1217
Number of pages5
JournalSupportive Care in Cancer
Volume15
Issue number10
DOIs
Publication statusPublished - Oct 2007

Fingerprint

Venous Thromboembolism
Aspirin
Veins
Catheters
Breast Neoplasms
Drug Therapy
Venous Thrombosis
Doppler Color Ultrasonography
Safety
Epistaxis
Incidence
Stomach
Prospective Studies
Confidence Intervals
Hemorrhage
Hypertension

Keywords

  • Breast cancer
  • Low-dose aspirin
  • Venous thromboembolism

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

@article{1a0fbffd7cf44e75be6ab361a0ad727b,
title = "Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter",
abstract = "Background: We previously demonstrated a high incidence (7.7{\%}) of venous thromboembolism (VTE) in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheters (CVC). The aim of this study was to evaluate the efficacy and safety of low-dose aspirin for the prevention of VTE. Patients and methods: In a monocentric prospective study, patients with stage II-IV breast cancer, who underwent CVC insertion for continuous infusional chemotherapy, were assigned to receive low-dose aspirin (100 mg daily). Treatment was started after CVC implantation and continued until the last day of chemotherapy. Patients were assessed for safety and for the incidence of symptomatic deep venous thrombosis (DVT) confirmed by color-Doppler ultrasonography. Results: Between April 2000 and March 2004, 188 consecutive patients were included in the study. Median age was 48 years (range 22-83), 31 patients (16{\%}) had concomitant hypertension, and 14 patients (7.4{\%}) were smokers. Median duration of treatment with aspirin was 3.6 months (range 0.4-5.7). A DVT confirmed by color-Doppler ultrasonography was observed in four patients (2.1{\%}; 95{\%} confidence interval, 0.58-5.35{\%}). Side effects included mild epistaxis (three patients, 1.5{\%}) and mild gastric pain (two patients, 1{\%}). No major bleeding complication or International Normal Ratio alteration occurred. Conclusions: Administration of low-dose aspirin is safe and seems to correlate with a low risk of DVT in breast cancer patients treated with infusional chemotherapy. Further randomized studies comparing low-dose aspirin with other anticoagulative agents are warranted.",
keywords = "Breast cancer, Low-dose aspirin, Venous thromboembolism",
author = "Giuseppe Curigliano and Alessandra Balduzzi and Anna Cardillo and Raffaella Ghisini and Giulia Peruzzotti and Laura Orlando and Rosalba Torrisi and Silvia Dellapasqua and Loredana Lunghi and Aron Goldhirsch and Marco Colleoni",
year = "2007",
month = "10",
doi = "10.1007/s00520-007-0277-0",
language = "English",
volume = "15",
pages = "1213--1217",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter

AU - Curigliano, Giuseppe

AU - Balduzzi, Alessandra

AU - Cardillo, Anna

AU - Ghisini, Raffaella

AU - Peruzzotti, Giulia

AU - Orlando, Laura

AU - Torrisi, Rosalba

AU - Dellapasqua, Silvia

AU - Lunghi, Loredana

AU - Goldhirsch, Aron

AU - Colleoni, Marco

PY - 2007/10

Y1 - 2007/10

N2 - Background: We previously demonstrated a high incidence (7.7%) of venous thromboembolism (VTE) in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheters (CVC). The aim of this study was to evaluate the efficacy and safety of low-dose aspirin for the prevention of VTE. Patients and methods: In a monocentric prospective study, patients with stage II-IV breast cancer, who underwent CVC insertion for continuous infusional chemotherapy, were assigned to receive low-dose aspirin (100 mg daily). Treatment was started after CVC implantation and continued until the last day of chemotherapy. Patients were assessed for safety and for the incidence of symptomatic deep venous thrombosis (DVT) confirmed by color-Doppler ultrasonography. Results: Between April 2000 and March 2004, 188 consecutive patients were included in the study. Median age was 48 years (range 22-83), 31 patients (16%) had concomitant hypertension, and 14 patients (7.4%) were smokers. Median duration of treatment with aspirin was 3.6 months (range 0.4-5.7). A DVT confirmed by color-Doppler ultrasonography was observed in four patients (2.1%; 95% confidence interval, 0.58-5.35%). Side effects included mild epistaxis (three patients, 1.5%) and mild gastric pain (two patients, 1%). No major bleeding complication or International Normal Ratio alteration occurred. Conclusions: Administration of low-dose aspirin is safe and seems to correlate with a low risk of DVT in breast cancer patients treated with infusional chemotherapy. Further randomized studies comparing low-dose aspirin with other anticoagulative agents are warranted.

AB - Background: We previously demonstrated a high incidence (7.7%) of venous thromboembolism (VTE) in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheters (CVC). The aim of this study was to evaluate the efficacy and safety of low-dose aspirin for the prevention of VTE. Patients and methods: In a monocentric prospective study, patients with stage II-IV breast cancer, who underwent CVC insertion for continuous infusional chemotherapy, were assigned to receive low-dose aspirin (100 mg daily). Treatment was started after CVC implantation and continued until the last day of chemotherapy. Patients were assessed for safety and for the incidence of symptomatic deep venous thrombosis (DVT) confirmed by color-Doppler ultrasonography. Results: Between April 2000 and March 2004, 188 consecutive patients were included in the study. Median age was 48 years (range 22-83), 31 patients (16%) had concomitant hypertension, and 14 patients (7.4%) were smokers. Median duration of treatment with aspirin was 3.6 months (range 0.4-5.7). A DVT confirmed by color-Doppler ultrasonography was observed in four patients (2.1%; 95% confidence interval, 0.58-5.35%). Side effects included mild epistaxis (three patients, 1.5%) and mild gastric pain (two patients, 1%). No major bleeding complication or International Normal Ratio alteration occurred. Conclusions: Administration of low-dose aspirin is safe and seems to correlate with a low risk of DVT in breast cancer patients treated with infusional chemotherapy. Further randomized studies comparing low-dose aspirin with other anticoagulative agents are warranted.

KW - Breast cancer

KW - Low-dose aspirin

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=34648824592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34648824592&partnerID=8YFLogxK

U2 - 10.1007/s00520-007-0277-0

DO - 10.1007/s00520-007-0277-0

M3 - Article

C2 - 17578607

AN - SCOPUS:34648824592

VL - 15

SP - 1213

EP - 1217

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 10

ER -